- Home
- NEOV vs VERU Comparison
NEOV vs VERU Comparison
Compare NEOV & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- VERU
- Stock Information
- Founded
- NEOV 2018
- VERU 1971
- Country
- NEOV United States
- VERU United States
- Employees
- NEOV N/A
- VERU N/A
- Industry
- NEOV Industrial Machinery/Components
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- VERU Health Care
- Exchange
- NEOV Nasdaq
- VERU Nasdaq
- Market Cap
- NEOV 111.3M
- VERU 108.8M
- IPO Year
- NEOV N/A
- VERU 1990
- Fundamental
- Price
- NEOV $3.21
- VERU $0.57
- Analyst Decision
- NEOV Strong Buy
- VERU Strong Buy
- Analyst Count
- NEOV 1
- VERU 4
- Target Price
- NEOV $7.50
- VERU $4.00
- AVG Volume (30 Days)
- NEOV 279.1K
- VERU 6.2M
- Earning Date
- NEOV 02-10-2025
- VERU 02-13-2025
- Dividend Yield
- NEOV N/A
- VERU N/A
- EPS Growth
- NEOV N/A
- VERU N/A
- EPS
- NEOV N/A
- VERU N/A
- Revenue
- NEOV $2,524,931.00
- VERU $16,886,419.00
- Revenue This Year
- NEOV $85.10
- VERU N/A
- Revenue Next Year
- NEOV $281.25
- VERU N/A
- P/E Ratio
- NEOV N/A
- VERU N/A
- Revenue Growth
- NEOV N/A
- VERU 22.46
- 52 Week Low
- NEOV $0.63
- VERU $0.49
- 52 Week High
- NEOV $6.11
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- NEOV 40.94
- VERU 44.48
- Support Level
- NEOV $2.95
- VERU $0.49
- Resistance Level
- NEOV $3.72
- VERU $0.56
- Average True Range (ATR)
- NEOV 0.29
- VERU 0.05
- MACD
- NEOV 0.06
- VERU 0.00
- Stochastic Oscillator
- NEOV 33.77
- VERU 63.62
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.